Protocol Ledger

NCT05633615 · Phase II · RECRUITING

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Interventional Phase II clinical trial protocol NCT05633615 sponsored by SWOG Cancer Research Network in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-12 Enrollment: 396 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05633615
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)396 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05633615
Protocol FieldVerified Registry Value
NCT IdentifierNCT05633615
Consolidated Lead SponsorSWOG Cancer Research Network
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment396 participants (ESTIMATED)
Registered Start Date2023-06-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI